Venus Remedies Receives Marketing Authorisation for Antibiotic Combination in Indonesia

Venus Remedies Limited has been granted marketing authorisation in Indonesia for its antibiotic combination Ceftazidime + Avibactam by the relevant Indonesian drug regulatory authority. This marks the first marketing authorisation for Ceftazidime + Avibactam for the Company in Indonesia and is indicated for the treatment of serious infections caused by multi-drug resistant gram-negative pathogens. Indonesia is a significant market for antibiotics due to the high burden of infectious diseases and growing focus on antimicrobial resistance. This authorisation enables the Company to commercialise the product in Indonesia through its existing distribution partnerships and is expected to enhance the Company’s presence in this strategically important market for anti-infectives. The development aligns with the Company’s strategy of expanding its footprint in South-East Asia and strengthening its portfolio of high-barrier-to-entry therapies.